Titan Biotech Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 779371, "name": "Titan Biotech", "stock_name": "Titan Biotech", "full_name": "Titan Biotech Ltd", "name_url": "stocks-analysis/titan-biotech", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "407.05", "chg": 4.35, "chgp": "1.08%", "dir": 1, "prev_price": "402.70", "mcapval": "1,669.00 Cr", "mcap": "Micro Cap", "scripcode": 524717, "symbol": "", "ind_name": "Specialty Chemicals", "ind_code": 11, "sector_id": 74, "indexname": "India SENSEX", "isin": "INE150C01029", "curr_date": "Aug 07, 03:30 PM", "curr_time": "15:02 PM", "last_traded_at": "Aug 07, 03:30 PM IST", "bse_nse_vol": "18.96 k", "exc_status": "Active", "traded_date": "Aug 07, 2026", "traded_date_str": "2026 08 07", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/titan-biotech-779371-0&utm_source=Spage_Header_Score", "mojoone": { "text": "Part of MojoOne Strategy", "type": "MN", "url": "https://www.marketsmojo.com/mojopro/strategy/2", "ismore": 0, "all_data": [], "is_blur": 1, "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/titan-biotech-779371-0&utm_source=Spage_Score_PartofStrategies" } }, "news": { "results": [ { "title": "Titan Biotech Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/titan-biotech-ltd-is-rated-hold-by-marketsmojo-4133486", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/TitanBiotechLtd_mojoScore_4133486.png", "date": "2026-08-03 10:10:44", "description": "Titan Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing." }, { "title": "Titan Biotech Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/titan-biotech-ltd-is-rated-hold-by-marketsmojo-4117583", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/TitanBiotechLtd_mojoScore_4117583.png", "date": "2026-07-23 10:10:52", "description": "Titan Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook." }, { "title": "Titan Biotech Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/titan-biotech-ltd-is-rated-hold-by-marketsmojo-4097296", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/TitanBiotechLtd_mojoScore_4097296.png", "date": "2026-07-12 10:10:25", "description": "Titan Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 July 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Titan Biotech Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/titan-biotech-ltd-is-rated-hold-by-marketsmojo-4081472", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/TitanBiotechLtd_mojoScore_4081472.png", "date": "2026-07-01 10:10:43", "description": "Titan Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 July 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Titan Biotech Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/titan-biotech-ltd-is-rated-hold-by-marketsmojo-4065068", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/TitanBiotechLtd_mojoScore_4065068.png", "date": "2026-06-20 10:10:29", "description": "Titan Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 June 2026, providing investors with the most recent insights into its performance and outlook." }, { "title": "Titan Biotech Gains 0.24%: 4 Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/titan-biotech-gains-024-4-key-factors-driving-the-weeks-momentum-4052233", "imagepath": "", "date": "2026-06-13 17:09:58", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Stock opens strong at Rs.456.60, up 3.48%</p>\n <p><strong>2 June:</strong> Titan Biotech upgraded to Buy by MarketsMOJO</p>\n <p><strong>4 June:</strong> Technical momentum shifts to mildly bullish amid mixed signals</p>\n <p><strong>5 June:</strong> Week closes steady at Rs.442.30, outperforming Sensex</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.441.25</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.442.30..." }, { "title": "Titan Biotech Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/titan-biotech-ltd-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-4040420", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/TitanBiotechLtd_mojoScore_4040420.png", "date": "2026-06-09 08:24:00", "description": "Titan Biotech Ltd, a micro-cap player in the Specialty Chemicals sector, has seen its investment rating downgraded from Buy to Hold as of 8 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite robust recent financial performance and impressive long-term returns, evolving technical signals and valuation concerns have tempered the overall outlook." }, { "title": "Titan Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/titan-biotech-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4035253", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/TitanBiotechLtd_technicaldot_4035253.png", "date": "2026-06-04 08:03:40", "description": "Titan Biotech Ltd, a micro-cap player in the specialty chemicals sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the company’s long-term returns remain robust, prompting a reassessment of its technical outlook and investment potential." }, { "title": "Are Titan Biotech Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-titan-biotech-ltd-latest-results-good-or-bad-4032355", "imagepath": "", "date": "2026-06-02 19:26:39", "description": "Titan Biotech Ltd's latest financial results for Q4 FY26 reveal a mixed operational performance characterized by significant year-on-year growth alongside sequential declines. The consolidated net profit reached ₹6.73 crores, reflecting a notable year-on-year increase of 66.17%. However, this figure represents a decline of 21.10% compared to the previous quarter. Similarly, net sales for the quarter amounted to ₹48.83 crores, which is a substantial year-on-year growth of 38.84%, yet it shows a sequential decrease of 13.59% from Q3 FY26.\n\nThe operating margin for the quarter stood at 19.89%, marking a significant improvement of 690 basis points from the same quarter last year, indicating effective cost management and operational leverage despite inflationary pressures. The average return on equity (ROE) of 21.23% demonstrates strong capital efficiency, positioning the company favorably within its industry.\n\n..." } ], "total": 448, "sid": "779371", "stock_news_url": "https://www.marketsmojo.com/news/titan-biotech-779371" }, "announcements": [ { "caption": "Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2026.", "datetime": "05-Aug-2026", "details": "Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30 2026", "source": "BSE" }, { "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018", "datetime": "06-Jul-2026", "details": "Compliance certificate under Reg. 74(5) of SEBI (DP) Regulations 2018", "source": "BSE" }, { "caption": "Closure of Trading Window", "datetime": "23-Jun-2026", "details": "Closure of trading window", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "", "data": [ { "title": "BOARD MEETING", "txt": "13 Aug 2026" } ] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Titan Biotech Ltd has declared <strong>20%</strong> dividend, ex-date: 19 Sep 25", "dt": "2025-09-19", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Titan Biotech Ltd has announced <strong>2:10</strong> stock split, ex-date: 20 Feb 26", "dt": "2026-02-20", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Stock opens strong at Rs.456.60, up 3.48%

2 June: Titan Biotech upgraded to Buy by MarketsMOJO

4 June: Technical momentum shifts to mildly bullish amid mixed signals

5 June: Week closes steady at Rs.442.30, outperforming Sensex

Read full news article

Titan Biotech Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals

2026-06-09 08:24:00

Titan Biotech Ltd, a micro-cap player in the Specialty Chemicals sector, has seen its investment rating downgraded from Buy to Hold as of 8 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite robust recent financial performance and impressive long-term returns, evolving technical signals and valuation concerns have tempered the overall outlook.

Read full news article

Titan Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-06-04 08:03:40

Titan Biotech Ltd, a micro-cap player in the specialty chemicals sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the company’s long-term returns remain robust, prompting a reassessment of its technical outlook and investment potential.

Read full news article

Are Titan Biotech Ltd latest results good or bad?

2026-06-02 19:26:39

Titan Biotech Ltd's latest financial results for Q4 FY26 reveal a mixed operational performance characterized by significant year-on-year growth alongside sequential declines. The consolidated net profit reached ₹6.73 crores, reflecting a notable year-on-year increase of 66.17%. However, this figure represents a decline of 21.10% compared to the previous quarter. Similarly, net sales for the quarter amounted to ₹48.83 crores, which is a substantial year-on-year growth of 38.84%, yet it shows a sequential decrease of 13.59% from Q3 FY26. The operating margin for the quarter stood at 19.89%, marking a significant improvement of 690 basis points from the same quarter last year, indicating effective cost management and operational leverage despite inflationary pressures. The average return on equity (ROE) of 21.23% demonstrates strong capital efficiency, positioning the company favorably within its industry. ...

Read full news article